Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 6/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 5/20 | 0.47 |
| ▸ | CYP4Z1 | Q86W10 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.38 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.36 |
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404151 | 0.96 | CYP4A11 (0.46) | CYP4A11CYP4F2CYP4Z1CA2CYP4F11 | |
| SCHEMBL6554455 | 0.89 | THRA (0.43) | CYP4A11CYP4F2CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL6405545 | 0.87 | CYP4Z1 (0.41) | CYP4A11CYP4F2CYP4Z1CYP4F11CYP4F12 | |
| SCHEMBL9869627 | 0.75 | ALDH1A1 (0.50) | ALDH1A1CTDSP1 | |
| SCHEMBL4130116 | 0.74 | CYP4A11 (0.71) | CYP4A11CYP4F2CA2ALDH1A1 | |
| SCHEMBL6554503 | 0.73 | CYP4A11 (0.45) | CYP4A11CYP4F2CA2PPARAALDH1A1 | |
| SCHEMBL8866817 | 0.73 | CYP4F2 (0.57) | CYP4A11CYP4F2CA2PPARAALDH1A1 | |
| SCHEMBL31502353 | 0.73 | CYP4A11 (0.57) | CYP4A11CYP4F2CYP4Z1CA2CYP4F11 | |
| SCHEMBL5755875 | 0.71 | HPGD (0.44) | CA2ALDH1A1THRATHRB | |
| SCHEMBL6405063 | 0.71 | CYP4F2 (0.53) | CYP4A11CYP4F2ALDH1A1SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1487800-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003080581-A1 | PHENANTHRIDINONES AS PARP INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171101-A1 | Phenanthridinones as parp inhibitors | PARP1, PARP11, PARP2 | CYP4A11 2762/4885CYP4F2 3749/4885CYP4Z1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.